lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Since the fall of the Eastern European Marxist–Leninist regimes, the Soviet Union and a variety of African Marxist–Leninist regimes in 1991, only a few Marxist–Leninist parties remained in power. This include China, Cuba, Laos, and Vietnam. Most Marxist–Leninist communist parties outside of these nations have fared relatively poorly in elections, although other parties have remained or became a relative strong force. In Russia, the Communist Party of the Russian Federation has remained a significant political force, winning the 1995 Russian legislative election, almost winning the 1996 Russian presidential election, amid allegations of United States foreign electoral intervention, and generally remaining the second most popular party. In Ukraine, the Communist Party of Ukraine has also exerted influence and governed the country after the 1994 Ukrainian parliamentary election and again after the 2006 Ukrainian parliamentary election. The 2014 Ukrainian parliamentary election following the Russo-Ukrainian War and the annexation of Crimea by the Russian Federation resulted in the loss of its 32 members and no parliamentary representation. In Europe, several Marxist–Leninist parties remain strong. In Cyprus, Dimitris Christofias of AKEL won the 2008 Cypriot presidential election. AKEL has consistently been the first and third most popular party, winning the 1970, 1981, 2001, and 2006 legislative elections.
== Economic and industrial relevance == The oxidation of phenol substrates to their corresponding quinones are the primary cause of fruit and vegetable browning during ripening, handling, and processing. Enzymatic browning affects the nutritional quality and appearance of fruits and produce. Over half of fruit losses are estimated to occur as a result of enzymatic browning, and tropical produce are particularly vulnerable to this reaction. The loss of nutrients can occur due to the interaction of quinones, produced by the oxidation of diphenols, with the side chains of essential amino acids derived from plant proteins. In particular, thiol and amine functional groups on the side chains of amino acids are highly susceptible to quinone binding and alkylation. The key role of catechol oxidase in enzymatic browning makes it a common target for inhibition. While a number of inhibitory strategies exist such as high temperature treatments(70-90 °C) to eliminate catechol oxidase catalytic activity, a popular strategy is decreasing the pH with citric acid. Catechol oxidase is more catalytically active in the pH 4-8 range due to coordination of the histidine residues to the catalytic copper centers. The use of acids like citric acid to decrease the pH below this optimum range diminishes the binding of the enzyme to its active site copper because the protonation of histidine residues interferes with their ability to coordinate with the copper centers.
Philosopher Eric Voegelin stated that Marxism–Leninism is inherently oppressive, writing that the "Marxian vision dictated the Stalinist outcome not because the communist utopia was inevitable but because it was impossible." Criticism like this has itself been criticised for philosophical determinism, i.e. that the negative events in the movement's history were predetermined by their convictions, with historian Robert Vincent Daniels stating that Marxism was used to "justify Stalinism, but it was no longer allowed to serve either as a policy directive or an explanation of reality" during Stalin's rule. In contrast, E. Van Ree wrote that Stalin considered himself to be in "general agreement" with the classical works of Marxism until his death. Graeme Gill stated that Stalinism was "not a natural flow-on of earlier developments; [it was a] sharp break resulting from conscious decisions by leading political actors." Gill added that "difficulties with the use of the term reflect problems with the concept of Stalinism itself. The major difficulty is a lack of agreement about what should constitute Stalinism." Historians such as Michael Geyer and Sheila Fitzpatrick criticised the focus upon the upper levels of society and the use of Cold War concepts, such as totalitarianism, which have obscured the reality of Marxist–Leninist systems, such as that of the Soviet Union. Mervyn Matthews criticized Marxism–Leninism for failing to solve poverty, noting that a large number of people in the Soviet Union were still in poverty despite its planned economy.
One of its main functions is to regulate how many follicles are recruited from the resting pool, helping to control which one becomes dominant and is selected for ovulation. After this selection, AMH levels in that follicle drop. Because AMH is secreted by granulosa cells, which support and nourish the developing egg, its levels in the blood can be used as a marker to estimate a woman's ovarian reserve, or the number of remaining eggs. In cattle, AMH can be used to predict how many follicles a cow will develop for embryo transfer, helping select the best animals for breeding programs. AMH is also studied as a diagnostic marker for ovarian disorders, such as polyendocrine metabolic ovarian syndrome (PMOS).
Sources: en.wikipedia.org
Termination of elongation depends on the release factor eRF1 that recognizes all three stop codons. When a stop codon is reached, termination of the polypeptide occurs the ribosome is disassembled and the completed polypeptide is released. eRF3 is a ribosome-dependent GTPase that helps eRF1 release the completed polypeptide. The human genome encodes a few genes whose mRNA stop codons are surprisingly leaky: In these genes, termination of translation is inefficient due to special RNA bases in the vicinity of the stop codon. Leaky termination in these genes leads to translational readthrough of up to 10% of the stop codons of these genes. Some of these genes encode functional protein domains in their readthrough extension so that new protein isoforms can arise. This process has been termed 'functional translational readthrough'. When the A site of the ribosome is occupied by a stop codon (UAA, UAG, or UGA) on the mRNA, creating the primary structure of a protein. tRNA usually cannot recognize or bind to stop codons. Instead, the stop codon induces the binding of a release factor protein (RF1 & RF2) that prompts the disassembly of the entire ribosome/mRNA complex by the hydrolysis of the polypeptide chain from the peptidyl transferase center of the ribosome. Drugs or special sequence motifs on the mRNA can change the ribosomal structure so that near-cognate TRNAs are bound to the stop codon instead of the release factors. In such cases of 'translational readthrough', translation continues until the ribosome encounters the next stop codon.
Polylactic acid (PLA) is a synthetic biodegradable polymer widely used as a dermal filler for soft tissue augmentation, classified into two stereoisomeric forms: poly(L-lactic acid) (PLLA) and poly(D,L-lactic acid) (PDLLA), both of which are widely used as dermal fillers, though variations in their physicochemical properties may lead to differences in handling characteristics and clinical performance. Unlike hyaluronic acid fillers that provide immediate volume, PLLA particles remaining after carrier absorption are degraded into lactic acid, which enhances collagen synthesis by fibroblasts, while immune cells recognize PLLA as a foreign body, initiating macrophage recruitment that induces fibroblast recruitment and fibrotic tissue formation.
A fibroblast is a type of biological cell typically with a spindle shape that synthesizes the extracellular matrix and collagen, produces the structural framework (stroma) for animal tissues, and plays a critical role in wound healing. Fibroblasts are the most common cells of connective tissue in animals.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.